Shockwave Medical showcases cardiovascular innovations with 23 studies at EuroPCR 2025
Shockwave Medical, Inc., part of Johnson & Johnson MedTech and a global leader in the field of circulatory restoration, announced that data from 23 company-sp onsored and funded studies, including three late-breaking presentations, will be presented at EuroPCR 2025 to be held May 20-23rd in Paris. These studies will feature data from Shockwave’s pioneering cardiovascular portfolio, including its market-leading Shockwave Intravascular Lithotripsy (IVL) platform and innovative Reducer technology that are transforming the treatment of cardiovascular disease.1
“The breadth of research data being presented on our products at EuroPCR 2025 reflects our relentless drive to address the unmet needs of patients suffering from cardiovascular disease,” said Nick West, M.D., Chief Medical Officer, Shockwave Medical. “As a pioneer in IVL and coronary sinus reduction technologies, we are committed to harnessing these clinical insights to drive innovations that will shape new standards of treatment and help physicians improve treatment for their patients worldwide.”
Key data highlights are outlined below. A full list of presentations can be found online.
Late-Breaking Presentations:
EMPOWER CAD Study: Women with Calcified Coronary Arteries Treated with IVL. Room 242AB. May 20, 3:00 – 4:00 p.m. CEST, presented by Margaret McEntegart, M.D., Columbia University Medical Center.
EMPOWER CAD is a prospective, multi-center, all-female study investigating the use of coronary intravascular lithotripsy (IVL) for treating calcified lesions in women with coronary artery disease. It aims to confirm the benefits of IVL in a post-market, real-world, all-comers population of female patients.
Randomized Comparison of Lithotripsy vs. Conventional Preparation of Calcified Lesions (BALI). Room 242AB. May 20, 3:00 – 4:00 p.m. CEST, presented by Andreas Torp Kristensen, M.D., Arhus University Hospital.
BALI is a multicenter, randomized trial that will show whether routine addition of balloon lithotripsy improves outcomes compared with conventional preparation alone.
Rotational Atherectomy, Lithotripsy or Laser for Calcified Coronary Stenosis. One-Year Outcomes (RollerCoastr-EPIC22).2 Room 242AB. May 20, 3:00 – 4:00 p.m. CEST, presented by Alfonso Jurado, M.D., Ph.D., La Paz University Hospital.
RollerCoastr-EPIC22 is a randomized controlled trial that is investigating the effectiveness of rotational atherectomy (RA), excimer laser coronary angioplasty (ELCA), and intravascular lithotripsy (IVL) in treating calcified coronary stenosis, with a focus on one-year outcomes.
Poster Presentation: Coronary Sinus Reducer for Patients with Refractory Angina and Non-Obstructive Coronary Disease – ANOCA. May 22, 11:29 a.m. CEST, presented by Ranil de Silva, M.D., Imperial College London.
In addition to the data being presented at EuroPCR, Shockwave Medical will support educational programs, in-booth presentations and training opportunities for attendees throughout the meeting, including two sponsored session symposia:
Treat Calcium Right the First Time: New Considerations for PCI Planning and Device Selection to Optimize Outcomes
Room 242AB. May 21, 12:30 – 2:00 p.m. CEST
Attendees will explore the role of IVL as a first-line treatment strategy for managing coronary artery calcification (CAC) by observing a recorded case and listening to a panel discussion.
o Moderator: Emanuele Barbato, M.D., Sant’Andrea University Hospital
o Panelists:
Angela McInerney, M.D., University Hospital Galway
Margaret McEntegart, M.D., Columbia University Medical Center
Niels Tuhe Olsen, Rigshospitalet
Marco Pavani, M.D., AOU San Luigi Gonzaga
Simon Wilson, M.D., St George’s University NHS Trust
Road to Relief – Effective Treatment for Patients with Refractory Angina with Shockwave Reducer
Room 251. May 22, 12:30 – 1:30 p.m. CEST
Attendees will hear from panelists to understand the true impact and occurrence of refractory angina, a major public health problem that has a treatment option.
o Moderator: James Spratt, M.D., St. George’s University NHS Trust
o Panelists:
Ranil de Silva, M.D., Royal Brompton Hospital
Mariusz Tomaniak, M.D., Ph.D., FESC, Medical University of Warsaw
Felix Woitek, M.D., University Hospital Carl Gustav Carus Dresden Heart Center
Tommaso Gori, M.D., Ph.D., University Medical Center Johannes Gutenberg University Mainz
Finally, Shockwave Medical’s IVL and Reducer technology will be prominently showcased across 13 scientific sessions of interest:
Tuesday, May 20
· Coronary Sinus Reducer Implantation: When All is Not Lost – The Exchange. May 20, 1:15 – 2:15 p.m. CEST, presented by Kevin Cheng
Wednesday, May 21
· Optimizing our Approach to Calcium Treatment – The Exchange. 8:30 – 9:30 a.m. CEST, presented by Breda Hennessey and Yongcheol Kim
· Calcified Nodules: A Different Beast? – Theatre Bleu. 8:30 – 9:30 a.m. CEST, presented by Emanuele Barbato
· A National Audit of Coronary Sinus Reducer Implantation in the United Kingdom – Abstracts Room 342B. 9:45 – 10:45 a.m. CEST, presented by Kevin Cheng
· Safety and Efficacy of Intravascular Lithotripsy for Calcified Left Main Disease: A Subgroup Analysis of Shock India Registry – Abstract & Case Corner. 9:45 – 10:45 a.m. CEST, presented by Ankush Gupta
· Coronary Lithotripsy in Calcified Lesions: Preliminary Results from the GISE Shockcalcium Registry – Room 241. 11:15 a.m. – 12:15 p.m. CEST, presented by Guilia Nardi
· Treatment of Refractory Angina Pectoris Associated with Coronary Microcirculation Dysfunction – Abstract & Case Corner B. 3:00 – 4:00 p.m. CEST, presented by Szymon Wlodarczak
Thursday, May 22
· Calcium Modification: Contemporary Comparisons of Atherectomy and IVL – Room 241. 8:30 – 9:30 a.m. CEST, presented by Pedro Lemos and Sheeran Al Shaikh
· Coronary Sinus Reducer for Patients with Refractory Angina & Non-Obstructive Coronary Disease (REDUCER I – ANOCA) – The Exchange. 11:15 a.m. – 12:15 p.m. CEST, presented by Ranil de Silva
· FRANCE-LILI Registry: Advancing Intravascular Lithotripsy in In-Stent Restenosis Treatment – Room 341, 1:45 – 2:45 p.m. CEST, presented by Guillaume Cayla
· Efficacy of CS Reducer in Refractory Angina Pectoris Associated with Microvascular Dysfunction – Room Arlequin. 3:00 – 4:00 p.m. CEST, presented by Szymon Wlodarczak
· Effectiveness of Coronary Sinus Reducer Implantation in a Routine Clinical Practice: 12-month Outcomes – Room Arlequin. 3:00 – 4:00 p.m. CEST, presented by Szymon Wlodarczak
· Intravascular Coronary Lithotripsy Prior to DCB Angioplasty – Room 252A. 4:15 – 5:15 p.m. CEST, presented by Franz Kleber
Shockwave Medical will be offering three days of valuable training village sessions with an immersive IVL virtual reality experience as well as best practice presentations and hands-on simulator lessons with both Shockwave IVL and Shockwave Reducer technology. For more information on Shockwave Medical’s presence at EuroPCR and to register for hands-on sessions, please visit our EuroPCR 2025 microsite. Visit us at EuroPCR in booth F19 and learn more about our portfolio online.
